Finlands Akademi
Finansieringsbeslut
 
Namn Myöhänen, Timo
Organisation HY
Projektets titel Prolyl oligopeptidase ligands - a possibility for a common drug therapy for several neurodegenerative diseases?
Beslutnr 305710
Beslutsdatum 30.09.2016
Finansieringsperiod 01.10.2016 - 30.09.2018
Finansiering 298 746
WebFOCUS Report
Beskrivning av projektet
The aim of the project was to clarify if PREP inhibitors that have been effective in the models of Parkinson's disease would be effective in other models of neurodegenerative diseases with protein accumulation. Additionally, the aim was to develop novel and patentable PREP inhibitors for further drug development. In the project, novel compounds were synthesized in collaboration with medicinal chemistry and tested in various cell culture models. The best compounds were thereafter tested in Parkinson's disease mouse model. We found completely novel PREP inhibitor structure that was equally effective as traditional inhibitors in cellular models of Parkinson's diseases, multiple system atrophy and Alzheimer's diseases. Moreover, compound successfully restored behavioral deficit in Parkinson's mouse model when administered after symptoms occurred. Taken together, our results support further development of PREP inhibitors as drugs applicable for several neurodegenerative diseases.